Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIIB
stocks logo

BIIB

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.33B
-5.6%
4.071
-22.89%
2.28B
-7.38%
4.024
-1.38%
2.23B
-8.97%
3.811
+10.79%
Estimates Revision
The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -11.04%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.49%
In Past 3 Month
Stock Price
Go Down
down Image
-11.04%
In Past 3 Month
30 Analyst Rating
up Image0
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 169.72 USD with a low forecast of 115.00 USD and a high forecast of 260.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
16 Hold
0 Sell
Moderate Buy
up Image0
Current: 123.160
sliders
Low
115.00
Averages
169.72
High
260.00
up Image0
Current: 123.160
sliders
Low
115.00
Averages
169.72
High
260.00
JP Morgan
Chris Schott
Hold
Maintains
$185 → $175
2025-05-05
Reason
JP Morgan
Chris Schott
Price Target
$185 → $175
2025-05-05
Maintains
Hold
Reason
JPMorgan lowered the firm's price target on Biogen to $175 from $185 and keeps a Neutral rating on the shares. The analyst updated the company's model post the Q1 report.
Needham
Ami Fadia
Hold
Reiterates
n/a
2025-05-02
Reason
Needham
Ami Fadia
Price Target
n/a
2025-05-02
Reiterates
Hold
Reason
Baird
Brian Skorney
Buy
Maintains
$300 → $255
2025-05-02
Reason
Baird
Brian Skorney
Price Target
$300 → $255
2025-05-02
Maintains
Buy
Reason
Baird analyst Brian Skorney lowered the firm's price target on Biogen to $255 from $300 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they beat on both top and bottom line which were mitigated by questions on Leqembi growth.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$241 → $187
2025-05-02
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$241 → $187
2025-05-02
Maintains
Strong Buy
Reason
Canaccord Genuity
Sumant Kulkarni
Strong Buy
Maintains
$265 → $220
2025-05-02
Reason
Canaccord Genuity
Sumant Kulkarni
Price Target
$265 → $220
2025-05-02
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Biogen to $220 from $265 and keeps a Buy rating on the shares. The firm noted Q1 results beat consensus and they are encouraged by the solid top-line performance, and EPS actually came in higher than had been expected. Execution will remain the key as they expect more focus on growth and the pipeline in 2026.
RBC Capital
Brian Abrahams
Buy
Maintains
$217 → $205
2025-05-02
Reason
RBC Capital
Brian Abrahams
Price Target
$217 → $205
2025-05-02
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on Biogen to $205 from $217 but keeps an Outperform rating on the shares. The company's Q1 results reaffirm that it can still effectively grow their launch products, execute on legacy products, keep costs down, and improve the pipeline mix, the analyst tells investors in a research note. Biogen looks to be emerging as a leaner and less-risky story with a heavily-discounted multiple, the firm adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 7.56, compared to its 5-year average forward P/E of 14.09. For a more detailed relative valuation and DCF analysis to assess Biogen Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
14.09
Current PE
7.56
Overvalued PE
17.46
Undervalued PE
10.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
10.23
Current EV/EBITDA
5.91
Overvalued EV/EBITDA
12.66
Undervalued EV/EBITDA
7.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
3.56
Current PS
1.91
Overvalued PS
4.26
Undervalued PS
2.87

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1169.89% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BIIB News & Events

Events Timeline

(ET)
2025-05-01
07:03:48
Biogen says Phase 2b LUMA study has fully enrolled
select
2025-05-01
06:57:09
Biogen sees FY25 EPS of $14.50-$15.50, consensus $15.20
select
2025-05-01
06:52:26
Biogen reports Q1 EPS $3.02, consensus $2.96
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
05-12Newsfilter
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

  • Promotions at Jeito Capital: Jeito Capital has promoted Mehdi Ainouche to Partner and Julien Elric to Senior Principal, reflecting the firm's growth and commitment to internal talent development in the biopharma sector.

  • Background of Promoted Individuals: Both Mehdi and Julien bring extensive experience in life sciences investment, with significant contributions to successful deals and portfolio management, enhancing Jeito's strategic focus on innovative medical solutions.

Preview
4.5
05-07NASDAQ.COM
Stocks Retreat on Concerns About Economic Damage from Tariffs

  • Market Performance: Major US stock indexes closed lower on Tuesday, influenced by concerns over economic impacts from trade wars and disappointing earnings reports, with the S&P 500 down -0.77% and a record trade deficit reported for March.

  • Interest Rates and Economic Outlook: The FOMC is expected to maintain current interest rates during its meeting, while market focus remains on tariffs and trade policy changes; recent economic data has reduced expectations for immediate rate cuts.

Preview
4.0
05-03Benzinga
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $205

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

  • Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 123.16 USD — it has decreased -1 % in the last trading day.

arrow icon

What is Biogen Inc (BIIB)'s business?

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

arrow icon

What is the price predicton of BIIB Stock?

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 169.72 USD with a low forecast of 115.00 USD and a high forecast of 260.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.43B USD, increased 6.13 % YoY.

arrow icon

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to 1.64 USD, decreased -39.26 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biogen Inc (BIIB)'s fundamentals?

The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -11.04%.
arrow icon

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7570 emplpoyees as of May 14 2025.

arrow icon

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 18.08B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free